PLX

Protalix Biother

2.90

0.17+6.23%

After Hours: 2.880 -0.02 -0.68%19:47 02/04 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE2.740/2.730

TODAY RANGE2.740-2.970

VOL2.58M

MARKET CAP233.22M

52 WEEK RANGE1.320-3.100

AVG VOL (3M)803.45K

% TURNOVER3.21%

TURNOVER--

P/E (TTM)62.91

% RANGE8.42%

EPS(TTM)0.0461

P/E(FORWARD)116.00

P/B4.404

BVPS0.6585

DIVIDEND--

P/S4.119

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP209.38M

SHARES OUTSTANDING80.42M

NEXT EARNINGS03/16-03/20

FREE FLOAT72.20M

LOT SIZE1

EX-DATE12/20/2019

News

Press Releases

Financial Reports

Profile

TipRanks·1d ago
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT)
Seeking Alpha·3d ago
A March Decision That Could Change Protalix BioTherapeutics Outlook
Seeking Alpha·5d ago
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy
TipRanks·5d ago
Protalix Wins EMA Panel Backing for New Elfabrio Dosing
TipRanks·5d ago
Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing
TipRanks·01/05 12:19
Protalix outlines 2026 rare-disease growth and pipeline strategy
PR Newswire·01/05 11:50
Protalix BioTherapeutics Letter to Stockholders
TipRanks·12/24/2025 02:01
Top Executive Makes Bold Insider Move on Protalix Stock
Seeking Alpha·12/22/2025 20:15
BioMarin: Amicus Buyout Sparks My Enthusiasm
TipRanks·12/19/2025 11:15
Protalix: Pipeline Expansion and Elfabrio Growth Drive Attractive Risk‑Reward and Undervalued Buy Rating
Seeking Alpha·12/17/2025 15:27
Protalix, Secarna in agreement to develop rare kidney disorder therapies
NASDAQ·12/17/2025 12:24
Protalix, Secarna Partner To Develop ASO Treatments For Rare Renal Conditions
PR Newswire·12/17/2025 11:50
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Dow Jones·11/21/2025 11:31
Protalix BioTherapeutics Price Target Cut to $12.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones·11/21/2025 11:31
Protalix BioTherapeutics Is Maintained at Buy by HC Wainwright & Co.

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-3.42%

822.00

Biogen Inc

BIIB

+4.92%

185.45

Amgen Inc

AMGN

+8.15%

366.20

Shire

SHPG

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+26.36%

0.0949

Lilly Eli & Co

LLY

+10.33%

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

-3.43%

2.25

Johnson & Johnson

JNJ

+0.59%

234.47

Abbvie Inc

ABBV

-3.79%

217.11

Zoetis Inc

ZTS

+3.50%

126.70

Gilead Sciences Inc

GILD

+2.06%

146.23

Novo-Nordisk A/S

NVO

-6.18%

47.19

Bristol-Myers Squibb Co

BMY

+2.91%

57.62

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+3.92%

26.78

Sanofi FR

SNY

+1.24%

48.08

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+2.04%

152.91

Dr Reddys Labs

RDY

+1.38%

14.00

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.